 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
16 News |  |
- sulcardine (HBI-3000) / HUYA Bioscience
Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety (Station 1 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_4611;
Acute IV HBI-3000 administration resulted in no clinically significant safety findings, LVEF depression, or DDI with CYP2D6. Sulcardine facilitates QT prolongation, which has a therapeutic benefit in terminating AF, with simultaneous uncoupling and reversing of the JTpc interval increase, a potential mechanism for reducing proarrhythmic risk due to excessive QT prolongation.
- || sulcardine (HBI-3000) / HUYA Bioscience
Enrollment closed, Trial completion date, Trial primary completion date: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) (clinicaltrials.gov) - Feb 28, 2024
P2, N=150, Active, not recruiting, Sponsor: HUYABIO International, LLC.
Sulcardine facilitates QT prolongation, which has a therapeutic benefit in terminating AF, with simultaneous uncoupling and reversing of the JTpc interval increase, a potential mechanism for reducing proarrhythmic risk due to excessive QT prolongation. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- || sulcardine (HBI-3000) / HUYA Bioscience
Trial completion, Enrollment change: Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects (clinicaltrials.gov) - Jul 15, 2022
P1, N=39, Completed, Sponsor: HUYABIO International, LLC.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Completed | N=24 --> 39
- || sulcardine (HBI-3000) / HUYA Bioscience
PK/PD data, Preclinical, Journal: Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate. (Pubmed Central) - Mar 1, 2022
Recruiting --> Completed | N=24 --> 39 Our study systematically explored the pharmacokinetic characteristics of Sul and successfully developed the PBPK model to predict of its clinical PK.
- ||| sulcardine (HBI-3000) / HUYA Bioscience
Enrollment open: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) (clinicaltrials.gov) - Jun 18, 2021
P2, N=150, Recruiting, Sponsor: HUYA Bioscience International
Our study systematically explored the pharmacokinetic characteristics of Sul and successfully developed the PBPK model to predict of its clinical PK. Not yet recruiting --> Recruiting
- | sulcardine (HBI-3000) / HUYA Bioscience
Enrollment status: Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects (clinicaltrials.gov) - Jun 16, 2021
P1, N=24, Recruiting, Sponsor: HUYA Bioscience International
Not yet recruiting --> Recruiting Enrolling by invitation --> Recruiting
- || sulcardine (HBI-3000) / HUYA Bioscience
Trial initiation date: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) (clinicaltrials.gov) - Apr 25, 2021
P2, N=150, Not yet recruiting, Sponsor: HUYA Bioscience International
Enrolling by invitation --> Recruiting Initiation date: Jan 2021 --> Apr 2021
- || sulcardine (HBI-3000) / HUYA Bioscience
Enrollment open: Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects (clinicaltrials.gov) - Feb 22, 2021
P1, N=24, Enrolling by invitation, Sponsor: HUYA Bioscience International
Initiation date: Jan 2021 --> Apr 2021 Not yet recruiting --> Enrolling by invitation
- |||| sulcardine (HBI-3000) / HUYA Bioscience
New P2 trial: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) (clinicaltrials.gov) - Dec 22, 2020
P2, N=150, Not yet recruiting, Sponsor: HUYA Bioscience International
- || sulcardine (HBI-3000) / HUYA Bioscience
New P1 trial: Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects (clinicaltrials.gov) - Dec 1, 2020
P1, N=24, Not yet recruiting, Sponsor: HUYA Bioscience International
- sulcardine (HBI-3000) / HUYA Bioscience
HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation - Phase 1 Study Results (Zone 2, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_5421;
Its strong reduction of JTp may predict freedom from arrhythmias associated with I Kr block. Based on these results and preclinical data indicating low proarrhythmic risk, the drug is now entering Phase 2 in recent onset AF.
- | sulcardine (HBI-3000) / HUYA Bioscience
Journal: Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound. (Pubmed Central) - May 2, 2019
The blockade of sulcardine on hNav1.5 channels was use-dependent. In conclusion, sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels and preferentially binds to both hERG and hNav1.5 channels in the open and inactivated states rather than in the resting state.
- | sulcardine (HBI-3000) / HUYA Bioscience
Trial completion: A Phase 1 Study of HBI-3000 (clinicaltrials.gov) - Aug 29, 2018
P1, N=47, Completed, Sponsor: HUYA Bioscience International
In conclusion, sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels and preferentially binds to both hERG and hNav1.5 channels in the open and inactivated states rather than in the resting state. Recruiting --> Completed
- ||| sulcardine (HBI-3000) / HUYA Bioscience
New P1 trial: A Phase 1 Study of HBI-3000 (clinicaltrials.gov) - Jan 16, 2018
P1, N=56, Recruiting, Sponsor: HUYA Bioscience International